It's not per­fect, but it's a good start: FDA pan­elists large­ly en­dorse Aim­mune's peanut al­ler­gy ther­a­py

Two days af­ter a fair­ly be­nign re­view from FDA staff, an in­de­pen­dent pan­el of ex­perts large­ly en­dorsed the ef­fi­ca­cy and safe­ty of Aim­mune’s peanut al­ler­gy ther­a­py, lay­ing the ground­work for ap­proval with a risk eval­u­a­tion and mit­i­ga­tion strat­e­gy (REMS).

Tra­di­tion­al­ly, peanut al­ler­gies are man­aged by avoid­ance, but the threat of ac­ci­den­tal ex­po­sure can­not be nul­li­fied. Some al­ler­gists have de­vised a way to dose pa­tients off-la­bel with peanut pro­tein de­rived from su­per­mar­ket prod­ucts to wean them off their al­ler­gies. But the idea be­hind Aim­mune’s prod­uct was to stan­dard­ize the peanut pro­tein, and track the process of de­sen­si­ti­za­tion — so when ac­ci­den­tal ex­po­sure in the re­al world in­vari­ably oc­curs, pa­tients are less like­ly to ex­pe­ri­ence a life-threat­en­ing al­ler­gic re­ac­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.